174 related articles for article (PubMed ID: 33648940)
1. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
4. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
[TBL] [Abstract][Full Text] [Related]
5. Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Clapper ML; Chang WL; Cooper HS
Cancer Prev Res (Phila); 2020 Mar; 13(3):229-240. PubMed ID: 32132117
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
Kowalczyk M; Sigorski D; Dyśko Ł; Zieliński E; Zupanovich Lucka D; Klepacki Ł
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556972
[TBL] [Abstract][Full Text] [Related]
8. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
9. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
10. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population.
Stingl JC; Ettrich T; Muche R; Wiedom M; Brockmöller J; Seeringer A; Seufferlein T
BMC Cancer; 2011 Aug; 11():360. PubMed ID: 21851602
[TBL] [Abstract][Full Text] [Related]
11. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Limburg PJ; Mahoney MR; Ziegler KL; Sontag SJ; Schoen RE; Benya R; Lawson MJ; Weinberg DS; Stoffel E; Chiorean M; Heigh R; Levine J; Della'Zanna G; Rodriguez L; Richmond E; Gostout C; Mandrekar SJ; Smyrk TC;
Cancer Prev Res (Phila); 2011 Feb; 4(2):259-69. PubMed ID: 21209397
[TBL] [Abstract][Full Text] [Related]
13. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.
Wali RK; Bianchi L; Kupfer S; De La Cruz M; Jovanovic B; Weber C; Goldberg MJ; Rodriguez LM; Bergan R; Rubin D; Tull MB; Richmond E; Parker B; Khan S; Roy HK
PLoS One; 2018; 13(4):e0193544. PubMed ID: 29617381
[TBL] [Abstract][Full Text] [Related]
14. Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence.
Uchiyama T; Takahashi H; Endo H; Kato S; Sakai E; Hosono K; Yoneda M; Inamori M; Hippo Y; Nakagama H; Nakajima A
Dig Endosc; 2012 Sep; 24(5):353-7. PubMed ID: 22925289
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin gallate inhibits dimethylhydrazine-induced colorectal cancer in rats.
Wang Y; Jin HY; Fang MZ; Wang XF; Chen H; Huang SL; Kong DS; Li M; Zhang X; Sun Y; Wang SM
World J Gastroenterol; 2020 May; 26(17):2064-2081. PubMed ID: 32536775
[TBL] [Abstract][Full Text] [Related]
16. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
17. Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice.
Wang X; Ye T; Chen WJ; Lv Y; Hao Z; Chen J; Zhao JY; Wang HP; Cai YK
World J Gastroenterol; 2017 Dec; 23(46):8128-8139. PubMed ID: 29290650
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.
Joe AK; Schnoll-Sussman F; Bresalier RS; Abrams JA; Hibshoosh H; Cheung K; Friedman RA; Yang CS; Milne GL; Liu DD; Lee JJ; Abdul K; Bigg M; Foreman J; Su T; Wang X; Ahmed A; Neugut AI; Akpa E; Lippman SM; Perloff M; Brown PH; Lightdale CJ
Cancer Prev Res (Phila); 2015 Dec; 8(12):1131-7. PubMed ID: 26471236
[TBL] [Abstract][Full Text] [Related]
19. A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.
Gillen DL; Meyskens FL; Morgan TR; Zell JA; Carroll R; Benya R; Chen WP; Mo A; Tucker C; Bhattacharya A; Huang Z; Arcilla M; Wong V; Chung J; Gonzalez R; Rodriguez LM; Szabo E; Rosenberg DW; Lipkin SM
Cancer Prev Res (Phila); 2015 Mar; 8(3):222-30. PubMed ID: 25604134
[TBL] [Abstract][Full Text] [Related]
20. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
